The most groundbreaking individual studies from the latest supplement and nutrition research — in plain language, with the evidence caveats built in. Research signals worth knowing about, not health advice.
This is a well-designed, double-blind trial with a large effect, but it's one of the first on this exact pairing, so the finding needs replication before it's a reliable recommendation.
This is an unusually large effect for a probiotic in acute diarrhea, but it comes from studies in a specific clinical population (hospitalized children in China), and the underlying trials don't appear to have been blinded — so the real-world benefit for adults or for milder cases could be smaller.
This is among the first systematic reviews on this question, so the picture is genuinely uncertain — the nearly 50% lower odds could be real or could be chance, and larger studies are needed before drawing conclusions.
This review suggests a link between B12 deficiency and hearing loss, but because the underlying studies didn't test supplementation directly and found no effect of age or treatment, the real-world takeaway is murkier than a simple 'low B12 hurts hearing.'
This meta-analysis suggests echinacea may substantially cut antibiotic prescriptions for children's upper respiratory infections, but because this is among the first major studies on this pairing, the findings need replication before we can be confident.
This meta-analysis links a specific probiotic to substantial reductions in two key inflammation markers, but since several related measures didn't budge and the evidence is still early, the overall anti-inflammatory role remains uncertain.
This is a small, early look at ginger's role in cold-weather performance, but the benefit was narrow and isolated; most other outcomes the study measured showed no effect, so the finding is intriguing but far from settled.
This is the first solid evidence linking vitamin D supplementation to lower fasting insulin in women with PCOS, but with only 3 studies in the analysis and mixed effect sizes, it's an early signal, not a settled conclusion.
This is among the first systematic reviews on aronia for weight loss, and it found no signal — so the popular idea that chokeberry helps shed pounds is not supported by the current evidence, though the picture could shift with larger or longer trials.
This is one of the first comprehensive reviews to challenge the popular idea that resveratrol meaningfully lowers blood sugar in people with type 2 diabetes, but the picture is now contested — not settled — because the underlying studies varied widely and had notable limitations.
This adds a small, positive signal to a body of evidence where two out of three prior studies found no effect, so the picture is still contested — not settled.
This meta-analysis suggests vitamin D may help frail older adults walk faster, but the evidence is thin and inconsistent — it’s a promising signal, not a settled fact.
This is one of the first large-scale analyses to suggest propolis may meaningfully improve blood sugar control in people with type 2 diabetes, but because the studies were done in a clinical setting and the dose wasn't specified, the finding is intriguing but far from a general recommendation.
This open-label, 402-person study is among the first to test this specific combination, and its null result challenges popular hopes that pairing B vitamins with D might boost brain function — but the finding applies only to a narrow clinical group, and the unblinded design means we should treat the hint of an effect with caution until larger, blinded trials weigh in.
This is among the first solid RCT data on blood orange for cognition, and it came up null for the average participant — the promising signal appeared only in a genetic subgroup, which means it's a preliminary lead, not a recommendation.
This is one of the first controlled trials to compare pea protein head-to-head with whey for glycemic control, so while the glucose effect is large and statistically robust, the contradictory insulin findings and the single-blind design mean we need replication before drawing firm conclusions.
This meta-analysis adds vitamin B6 to the list of options for pregnancy nausea, but the low-to-moderate quality evidence and limited side-effect reporting mean the true benefit could be smaller, and the lack of a specified dose makes it hard to apply directly.
This is an intriguing first look at spirulina for weight in a very specific clinical population; the effect is large and well-measured, but the results may not apply to healthy people looking to lose weight.
This meta-analysis is among the first to rigorously tally the trade-offs in this specific population, so the findings are a serious heads-up but not a final verdict — especially since the same analysis found no overall fracture prevention and a significant uptick in hypercalcemia risk.
This null result contradicts two earlier studies that suggested flax might help, so the overall picture is now genuinely contested — not settled.
This is a moderate-strength signal from four studies, all pointing in the same direction, but until more trials confirm it in non-diabetic populations and settle the dose, it's early evidence — not a prescription.
This is one of the first rigorous tests of olive oil in gestational diabetes, and while the 66% reduction in neonatal complications is striking, the effect was measured in a specific clinical population and several other outcomes (like weight gain) didn't budge, so the benefit may be narrower than it appears.
This large, double-blind RCT provides the first rigorous evidence that Cissus quadrangularis extract can raise GLP-1 levels in overweight adults, a promising signal for weight management — but because it's a single early study, caution is warranted until independent teams confirm the results.
This challenges the common assumption that stevia helps cut calories by suppressing appetite, but because the analysis rests on a small pool of clinical studies and couldn't directly test energy intake, the picture is far from settled.
This is one of the first meta-analyses to report a harmful effect on HOMA-B alongside clear benefits on other markers, so the picture is now genuinely contested — not settled.
This is one of the first indexed analyses to single out L. rhamnosus GG for complete pain resolution in a specific pediatric condition, so the result is promising but still early and may not apply to adults or general digestive discomfort.
This is the first well-controlled study to show oral Gotu Kola can measurably reduce wrinkle depth, but the evidence is still early and limited to one demographic, so it’s a promising signal, not a settled benefit.
For people hoping colostrum might ease general joint or muscle pain, this early study suggests it won't—though it did improve some aspects of recovery after a hip fracture. Because the population was clinical and the study is one of the first on this topic, the picture is far from settled.
This is the first decent-sized meta-analysis on selenium for RA joint pain, and the result is promising but preliminary: the pain relief was clear, yet the fact that inflammatory markers and stiffness didn't change means we still don't know why it worked or whether it generalises beyond this specific clinical group.
This well-designed but open-label trial challenges the popular notion that avocados are a brain food for memory, at least in overweight adults; the picture is now contested, and more blinded studies are needed to settle it.